Sign in Subscribe
Pharmaceutical industry

ImmunoGen to Present Nine Presentations at the 102nd Annual Meeting of the American Association for Cancer Research (AACR)

Strategic Insights

— 1 min read

At the upcoming 102nd Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, ImmunoGen scientists will present nine study abstracts, including eight posters and one oral presentation, showcasing the company's Targeted Antibody Payload (TAP) technology and its applications in cancer treatment. The presentations highlight the potential of TAP compounds, such as IMGN529 and IMGN853, in targeting various types of cancer cells.

Key Takeaways:

  • ImmunoGen will present nine study abstracts at the AACR meeting, highlighting the company's TAP technology and its applications in cancer treatment.
  • The presentations will focus on six preclinical compounds, including IMGN529 and IMGN853, which have shown promising results in targeting cancer cells.
  • IMGN529 features an antibody with pronounced anticancer activity, while IMGN853 employs a newer linker to combat multidrug resistance.
  • The TAP technology uses monoclonal antibodies to deliver a cancer-cell killing agent specifically to tumor cells.
  • ImmunoGen has six presentations on IMGN529, three on IMGN853, and two on other compounds, with additional data on lorvotuzumab mertansine (IMGN901) and Bayer HealthCare Pharmaceuticals' compound, BAY 94-9343.
  • The company's collaborations with major pharma partners, including Amgen, Bayer HealthCare Pharmaceuticals, Biogen Idec, Biotest, Genentech, Novartis, and sanofi-aventis, are also highlighted.
  • The most advanced compound using ImmunoGen's TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing through the Company's collaboration with Genentech.
  • ImmunoGen'snovel humanized anti-HER3 antibody, huHER3-8, has shown potential in inhibiting exogeneous ligand-independent proliferation of tumor cells.

Statistics:

  • Nine study abstracts will be presented at the AACR meeting by ImmunoGen scientists.
  • Six presentations will focus on IMGN529 and IMGN853, highlighting their potential in targeting cancer cells.
  • IMGN529 has been shown to have potent in vitro and in vivo activity against non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) cell lines.
  • Lorvotuzumab mertansine (IMGN901) has demonstrated immune effector activity and high activity in combination with paclitaxel/carboplatin therapy in preclinical models of ovarian cancer.

Sources:

  • "ImmunoGen, Inc. to Present at the 102nd Annual Meeting of the American Association for Cancer Research (AACR)" (April 2011)
  • ImmunoGen's website: www.immunogen.com

Read more